Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

A Phase III, multicenter, randomized study to compare the rate of complete response (CR) and duration of CR, in patients with TP53-mutated MDS who will receive APR-246 and azacitidine or azacitidine alone.
Not Available
Phase III
Adults
Not Available
Not Available
Byrne, Michael
International
Vanderbilt University
06-14-2019
Treatment
VICCHEM18178
NCT03745716

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Signed Informed Consent (ICF) and is able to comply with protocol requirements

Documented diagnosis of MDS, according to World Health Organization (WHO) classification

Patient has adequate organ function as defined by the following laboratory values:

Creatinine clearance > 30 mL/min (by Cockcroft-Gault method)

Total serum bilirubin
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
Age ?18 years at the time of signing the informed consent form (ICF)

Having at least one TP53 mutation which is not benign or likely benign

Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

If of childbearing potential, negative pre-treatment urine or serum pregnancy test

If of childbearing potential (males and females), willing to use an effective form of contraception such as latex condom, hormonal birth control, intrauterine device or double barrier method during chemotherapy treatment and for at least six months thereafter



Exclusion Criteria:

Patient has a known history of human immunodeficiency virus (HIV) or active hepatitis B or active hepatitis C infection (testing not mandatory)

Patient has any of the following cardiac abnormalities (as determined by treating MD):

Myocardial infarct within six months prior to registration,

New York Heart Association Class II or worse heart failure (Appendix II) or known left ventricular ejection fraction (LVEF)
A history of familial long QT syndrome,

Clinically significant pericardial disease

Electrocardiographic evidence of acute ischemia

Symptomatic atrial or ventricular arrhythmias not controlled by medications

QTc ? 470 msec (QT cardiac interval)

Bradycardia (
Concomitant malignancies or previous malignancies with less than a 1-year disease free interval at the time of signing consent. Patients with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g. cervix) may enroll irrespective of the time of diagnosis

Prior exposure to azacitidine, decitabine or investigational hypomethylating agent

Prior exposure to intensive chemotherapy

Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of MDS within 14 days of the first day of study drug treatment

No concurrent use of erythroid stimulating agents

Patients with history of allogeneic stem cell transplantation

Pregnant women are excluded from this study because APR-246 has not been studied in pregnant patients. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with APR 246, breastfeeding should be discontinued if the mother is treated with APR-246.

Patients with active uncontrolled infections

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: